Results 91 to 100 of about 5,430 (178)

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance

Viruses, 2015
Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries.
Bruno Roche, Audrey Coilly, Anne-Marie Roque-Afonso, Didier Samuel   +3 more
doaj   +1 more source

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection

, 2016
Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and white
Pyrsopoulos, Nikolaos, Jeffers, Lennox, George Kong, Morgan, Timothy R, Hughes, Eric, Luketic, Velimir, Paul J. Thuluvath, Natarajan Ravendhran, Maribel Rodriguez-Torres, Thuluvath, Paul J, Pearlman, Brian, Khallafi, Hicham, Steven-Huy Han, Rodriguez-Torres, Maribel, Eric Hughes, Lawitz, Eric, John M. Vierling, McPhee, Fiona, Velimir Luketic, Vierling, John M, Ghalib, Reem, Michelle Treitel, Treitel, Michelle, Kong, George, Christopher O’Brien, Rustgi, Vinod, Philip D. Yin, Bienvenido Yangco, Stephen Harrison, O'Brien, Christopher, Lennox Jeffers, Hicham Khallafi, Han, Steven-Huy, Timothy R. Morgan, Harrison, Stephen, Vinod Rustgi, Yin, Philip D, Eric Läwitz, Philippe J. Zamor, Zamor, Philippe J, Brian Pearlman, Fiona McPhee, Nikolaos Pyrsopoulos, Ravendhran, Natarajan, Reem Ghalib, Yangco, Bienvenido   +45 more
core   +1 more source

Additional file 1: of Ionic liquid-based vortex-assisted DLLME followed by RP-LC-PDA method for bioassay of daclatasvir in rat serum: application to pharmacokinetics

, 2019
Figure S1. The schematic diagram showing the IL-DLLME process of daclatasvir from rat serum. Figure S2. The systematic predictable mechanism and its phase separation of IL from rat serum. Figure S3.
T. Rao (6648269), Marakada Sridevi (6648272), Challa Naidu (6648275), Bandaru Nagaraju (6648278)   +3 more
core   +1 more source

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

, 2015
BACKGROUND & AIMS: Improved therapies for peginterferon/ribavirin null or partial responders are needed. This study evaluated daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) plus peginterferon alfa-2a and ribavirin in this ...
BRUNETTO, MAURIZIA ROSSANA, Everson, G, Kugelmas, M, Pol, S, Jensen, D., Vierling, J, Zeuzem, S, Serfaty, L, de Ledinghen, V, Elkhashab, M, Younes, Zh, Hézode, C, Hennicken, D, Bernstein, D, Sherman, Ke, Luketic, V, Mauss, S, Heo, J, Mcphee, F, Tran, A   +19 more
core   +2 more sources

Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients

, 2018
Aim. To estimate efficacy and safety of direct antiviral drugs for hepatitis C treatment in donor lung recipients. Key points. The first cases in Russian literature and one of the first-ever cases of hepatitis C treatment by direct antiviral agents in ...
N. A. Mukhin, V. T. Ivashkin, D. T. Abdurakhmanov, Ye. . Sidorova, I. N. Tikhonov   +4 more
core   +1 more source

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND DACLATASVIR DRUG PRODUCT BY RP-HPLC METHOD

, 2017
Analytical method was developed for the estimation of Sofosbuvir and Daclatasvir drug substance by liquid chromatography. The chromatographic separation was achieved on C18 column (XTerra RP18 150*4.6, 5um) at ambient temperature .The separation achieved
Benzil Dudekula1*, Dr.C.Ramachandraiah2, Dr.N.Devanna3
core   +1 more source

Daclatasvir-Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus–Induced Membranous Replication Factories, Independent of RNA Replication

, 2014
Background & AimsDirect-acting antivirals that target nonstructural protein 5A (NS5A), such as daclatasvir, have high potency against the hepatitis C virus (HCV).
Paul, David, Harak, Christian, Romero-Brey, Inés, Lohmann, Volker, Bartenschlager, Ralf, Berger, Carola, Zayas, Margarita, Penin, Francois, Hoppe, Simone, Terreux, Raphael, Radujkovic, Danijela, Gao, Min   +11 more
core   +1 more source

UEG Week 2025 Poster Presentations

United European Gastroenterology Journal, Volume 13, Issue S8, Page S803-S1476, October 2025.
wiley   +1 more source

Daclatasvir: potential role in hepatitis C [Corrigendum]

, 2014
Lee C. Drug Des Devel Ther. 2013;7:1223–1233. On page 1231 in the "Conclusion" section, line 3 contains incorrect information. The correct sentence is "This review summarizes key preclinical and clinical data of an HCV NS5A inhibitor,
Lee C
core  

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection

, 2015
Has a Supplementary Figure 1 on page 366.e1BACKGROUND & AIMS: Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of ...
BRUNETTO, MAURIZIA ROSSANA, Brunetto, M., Pol, S, Strasser, Si, de Lédinghen, V, Harley, H, Strasser, S., Hézode, C., Lee, S., Ghesquiere, W., Ramji, A, Fung, Sk, Ghesquiere, W, Zaltron, S, Dore, G., Weis, N, Fung, S., de Lédinghen, V., Dore, Gj, Tran, A., Weis, N., Larrey, D, Shafran, S., Zaltron, S., Taliani, G., Tatum, H., George, J, Harley, H., Hézode, C, Lawitz, E, Lee, Ss, Larrey, D., Tatum, Ha, Lawitz, E., Taliani, G, George, J., Shafran, Sd, Ramji, A., Pol, S., et al., Tran, A   +40 more
core   +1 more source